13F Holdings
中文EN

OGN Organon & Co.

Pharmaceutical Preparations · NYSE · SEC CIK 1821825 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.2%
TTM net income YoY-57.5%
TTM EPS YoY-59.2%
Revenue 3-yr CAGR-0.3%
Net income 3-yr CAGR-28.6%

Margins

Gross margin53.1%
Operating margin—
Net margin3.5%
FCF margin11.1%
EBITDA margin—

Returns

ROE20.3%
ROA1.6%
ROIC (approx.)—
Asset turnover0.45x

Leverage & solvency

Liabilities / assets91.1%
Debt / equity7.17x
Current ratio2.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.96x
Accruals ratio-4.7%
Payout ratio9.4%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.22B$6.40B$6.26B$6.17B$6.30B
Cost of revenue$2.90B$2.69B$2.52B$2.29B$2.38B
Gross profit$3.31B$3.71B$3.75B$3.88B$3.92B
R&D expense$366.00M$469.00M$528.00M$471.00M$339.00M
SG&A expense$1.72B$1.76B$1.89B$1.70B$1.67B
Interest expense$504.00M$520.00M$527.00M$422.00M$258.00M
Pretax income$425.00M$807.00M$673.00M$1.12B$1.53B
Income tax$238.00M-$57.00M-$350.00M$205.00M$178.00M
Net income$187.00M$864.00M$1.02B$917.00M$1.35B
EPS (basic)0.723.364.013.615.33
EPS (diluted)0.723.333.993.595.31
Dividends declared per share0.341.121.121.120.56
Weighted avg. shares (diluted)260.76M259.15M256.27M255.17M254.19M
Balance sheet
Cash & equivalents$574.00M$675.00M$693.00M$706.00M$737.00M
Receivables$1.33B$1.36B$1.74B$1.48B$1.38B
Inventory$1.41B$1.32B$1.31B$1.00B$915.00M
Current assets$4.35B$4.35B$4.51B$3.93B$3.76B
PP&E, net$1.30B$1.17B$1.18B$1.02B$973.00M
Goodwill$4.15B$4.68B$4.60B$4.60B$4.60B
Intangibles$1.13B$1.41B$533.00M$649.00M$651.00M
Total assets$12.87B$13.10B$12.06B$10.96B$10.68B
Current liabilities$2.39B$2.72B$2.92B$2.51B$2.60B
Short-term debt$16.00M$20.00M$9.00M$8.00M$9.00M
Long-term debt$8.63B$8.86B$8.75B$8.90B$9.12B
Total debt$8.64B$8.88B$8.76B$8.91B$9.13B
Total liabilities$12.12B$12.63B$12.13B$11.85B$12.19B
Shareholders' equity$752.00M$472.00M-$70.00M-$892.00M-$1.51B
Net debt$8.07B$8.21B$8.07B$8.21B$8.40B
Shares outstanding260.32M257.80M255.63M254.37M253.55M
Cash flow statement
Operating cash flow$700.00M$939.00M$799.00M$858.00M$2.16B
Capital expenditure$162.00M$175.00M$251.00M$196.00M$192.00M
Free cash flow$538.00M$764.00M$548.00M$662.00M$1.97B
Investing cash flow-$390.00M-$513.00M-$260.00M-$420.00M-$481.00M
Financing cash flow-$561.00M-$368.00M-$569.00M-$433.00M-$977.00M
Depreciation & amortization$156.00M$132.00M$120.00M$96.00M$92.00M
Stock-based compensation$77.00M$105.00M$101.00M$75.00M$59.00M
Dividends paid$88.00M$297.00M$294.00M$290.00M$145.00M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.